Genetic Analysis

Overview of Genetic Analysis

Genetic analysis encompasses a suite of techniques aimed at deciphering the genomic, transcriptomic, and epigenomic landscapes of biological systems. In cancer research, it is indispensable for identifying somatic mutations, copy number variations (CNVs), gene expression signatures, and epigenetic modifications that underpin tumorigenesis, heterogeneity, and response to therapy. Utilizing tumor organoids for genetic analysis offers a transformative approach, bridging the gap between conventional cell lines and in vivo models. These self-organizing 3D structures faithfully retain the genetic architecture and phenotypic diversity of the original tumor, providing a genetically representative and scalable platform for high-throughput sequencing, functional genomics, and longitudinal studies of clonal evolution.

Advantages of the Organoid Model for Genetic Analysis

Organoids provide a physiologically relevant and genetically stable system that overcomes key limitations of traditional models, enabling more accurate and reproducible genetic studies.

Application of Organoids in Genetic Analysis

Organoids are powerfully deployed across diverse genetic research applications, from biomarker discovery to mechanistic studies, as evidenced by current research.

Our Services

Drawing upon our extensive expertise in 3D cell culture and molecular biology, Alfa Cytology offers end-to-end genetic analysis services integrated with phenotypic drug testing. This powerful combination accelerates your drug discovery programs by directly linking genomic alterations to therapeutic response, enabling more informed decision-making from target identification to preclinical validation.

Specific Organoid Models Development for Genetic Analysis

Alfa Cytology develops bespoke tumor organoid models specifically optimized for robust genetic analysis. Our expertise encompasses organoids derived from a wide array of sources, including primary tumor tissues, PDX models, and iPSCs, and cultivated under various conditions (e.g., defined media, air-liquid interface) to preserve the native genetic context of the cancer subtype under investigation.

Advanced Organoid Platforms for Cancer Genetic Analysis

Alfa Cytology's services are built upon state-of-the-art, integrated platforms that combine physiologically relevant organoid cultivation with cutting-edge analytical technologies. These platforms, including microfluidic "Organoid-on-a-Chip" systems and complex co-cultures, are specifically engineered to preserve genetic and phenotypic tumor characteristics for definitive research outcomes.

Workflow for Organoid-Based Cancer Genetic Analysis

• Project Consultation & Design: Collaborative development of an analysis strategy targeting specific genetic hypotheses.
• Organoid Model Establishment & QC: Generation or selection of high-quality, passage-controlled organoids, with QC via STR profiling and baseline genotyping.
• Sample Preparation & Nucleic Acid Isolation: Optimized protocols for high-integrity DNA/RNA extraction from 3D organoid structures.
• Sequencing & Data Acquisition: Execution of chosen sequencing applications (WGS, WES, RNA-seq, targeted panels) on accredited platforms.
• Bioinformatic Analysis & Interpretation: Comprehensive pipeline for alignment, variant calling, CNV analysis, pathway enrichment, and biological significance interpretation.
• Functional Correlation & Reporting: Integration of genetic data with phenotypic drug response data from the same organoids, delivered in a detailed final report.

Customized Solutions for Cancer Genetic Analysis

Alfa Cytology moves beyond standardized packages to provide bespoke investigations. Our team collaborates closely with you to design and execute specialized solutions that delve deep into the molecular mechanisms of your specific cancer research questions.

Key Analyses of Organoid Model-based Genetic Testing

Understanding the functional consequences of genetic alterations is paramount to advancing oncology research. Our comprehensive genetic testing suite can deliver insights across multiple layers of genomic regulation.

• Somatic Variant Analysis: Detection and annotation of single-nucleotide variants (SNVs), insertions/deletions (Indels) from WES/WGS data, with filtering against germline and background organoid culture artifacts.
• Copy Number & Structural Variant Profiling: Identification of focal and chromosomal-level amplifications/deletions, gene fusions, and complex rearrangements using depth-of-coverage and split-read analysis.
• Transcriptomic & Gene Expression Signatures: RNA-seq analysis for differential expression, fusion transcript detection, and assignment of established molecular subtypes (e.g., CMS, PAM50).
• Clonal Deconvolution & Phylogenetics: Utilization of variant allele frequency (VAF) data from deep sequencing to reconstruct tumor clonal architecture and evolutionary trees.

Case Study-Genetic Profiling of Ovarian Cancer Organoids to Decipher Chemoresistance Mechanisms

To investigate the molecular basis of cisplatin resistance in ovarian cancer, Alfa Cytology developed a paired organoid model consisting of chemo-sensitive and chemo-resistant variants. A comprehensive genetic testing approach was applied, utilizing high-throughput sequencing to compare the transcriptomic profiles of these matched organoid sets. This analysis identified a substantial number of differentially expressed genes. Bioinformatics analysis revealed that biological processes related to cellular metabolism were significantly associated with the resistant phenotype. Further investigation highlighted the pronounced enrichment of a specific extracellular matrix-associated gene family in the resistant organoids. To assess the translational relevance of this finding, survival analysis was performed using independent datasets, which confirmed that high expression of the lead candidate gene was significantly correlated with poorer outcomes. The upregulated expression of this gene was further corroborated at both the RNA and protein levels within the resistant organoid models. This integrated study exemplifies how organoid-based genetic testing can support pinpointing robust biomarkers and elucidating mechanisms of drug resistance.

Fig.1 Comparative analysis of mRNA expression for the identified gene marker was conducted between matched chemo-resistant and chemo-sensitive ovarian cancer organoid models. Data are presented as mean ± SEM (n=5, **p < 0.01).

Why Choose Us?

• Proven Expertise: Deep specialization in both organoid biology and advanced genomic analysis, ensuring scientifically sound experimental design and data interpretation.
• End-to-End Partnership: A collaborative service model, providing support from model development through sequencing to the final bioinformatic report, ensuring project continuity and success.
• Cutting-Edge Technology Platform: Leverage cutting-edge sequencing technology and bioinformatic infrastructure, coupled with optimized protocols for organoid-specific sample preparation to ensure data of the highest quality and relevance.
• Data Rigor & Reproducibility: Commitment to the high standards of quality control, including routine genomic authentication and contamination screening, to deliver reliable, reproducible data for publication and decision-making.

Contact Us

Dedicated to empowering your cancer research with precise model systems and analytical depth, Alfa Cytology's genetic analysis services provide the clarity required to turn complex data into biological insights. Our dedicated team is ready to collaborate on developing a tailored genetic analysis project that addresses your specific research objectives and accelerates your path to discovery. Contact us today to discuss your project requirements and receive a detailed proposal.

For research use only.